For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

MOTS-c

Also known as: Mitochondrial Open reading frame of the Twelve S rRNA type-c

MOTS-c is an investigational mitochondrial-derived peptide studied preclinically for metabolic regulation. It is research-only and not FDA-approved; the CB4211 analog program (CohBar) was discontinued in 2023.

Where to buy · live market data

Who's worth your money for MOTS-c

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 49 scored sellers

$2.00/mg

$800 · 400mg · 99.2% purity

Best value

Lowest $/mg among scored sellers

$0.00/mg

— · 10mg · 99.8% purity

Most tested

50 independent COAs on file

$3.85/mg

$77.00 · 20mg · 99.3% purity

Average price

$4.40/mg

Sellers

81

45-day trend

-14.3%

72 of 81 sellers have a current price· 4 stale hidden· 19 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch MOTS-c

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About MOTS-c

CAS

1627580-64-6

Molecular formula

C101H152N28O22S2

Sequence

MRWQEMGYIFYPRKLR

Typical dose range

5–10 mg subcutaneous, 2–3 times per week (research use)

Half-life

~4–6 hours (estimated; exercise-induced endogenous levels return to baseline within ~4 hours)

Independent evidence

COAs for MOTS-c

355 third-party tests across 53 vendors. Each card links to the full report.

All 355 COAs for MOTS-c →
Measured purity 66.5%–100.0% across 235 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.58 %
Sep 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Sunrise Bioresearch· batch MOT10SEP26-01

✓ Vendor-published
99.58 %
Sep 2026
Freedom Diagnostics Moderate

For

MOTS-c

by Sunrise Bioresearch· batch MOT10SEP26-01

COA on file
Aggregated · 3rd-party listing
99.72 %
Sep 2026
Freedom Diagnostics Moderate

For

MOTS-C

by VoriLabs· batch MOT-K2609-A

Aggregated · 3rd-party listing
99.19 %
Sep 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Peptide Partners· batch PX-L916

Aggregated · 3rd-party listing
99.74 %
Sep 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Forge Performance Co.· batch MOTSC20-2609-01-BLK-SLV

Aggregated · 3rd-party listing
99.68 %
Aug 2026
Freedom Diagnostics Moderate

For

MOTS-C

by VeratisBio· batch MOTS0001

Aggregated · 3rd-party listing
99.47 %
Aug 2026
Freedom Diagnostics Moderate

For

MOTS-C

by VoriLabs· batch MOT-2608-A

Aggregated · 3rd-party listing
99.83 %
Aug 2026
ILS Labs Strong

For

MOTS-c

by Frontier Aminos· batch MS40-09

Aggregated · 3rd-party listing
99.32 %
Aug 2026
ILS Labs Strong

For

MOTS-C

by jdbioworks· batch 2026-003

Aggregated · 3rd-party listing
99.86 %
Aug 2026
Freedom Diagnostics Moderate

For

MOTS-C

by NovaForge Labs· batch NFL-0001

Aggregated · 3rd-party listing
99.41 %
Aug 2026
Freedom Diagnostics Moderate

For

MOTS-c

by Novaglo Research· batch 5004081226MC

Aggregated · 3rd-party listing
99.74 %
Jul 2026
ILS Labs Strong

For

MOTS-C

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.86 %
Jul 2026
ILS Labs Strong

For

MOTS-C

by Artisan Aminos· batch AA-MOTS10-049

Aggregated · 3rd-party listing
99.74 %
Jul 2026
ILS Labs Strong

For

MOTS-C

by Artisan Aminos· batch AA-MOTS40-049

Aggregated · 3rd-party listing
99.33 %
Jul 2026
Janoshik Analytical Limited

For

MOTS-C

by Verified Peptides· batch M007261420M

Aggregated · 3rd-party listing
99.27 %
Jul 2026
Janoshik Analytical Limited

For

MOTS-c

by CertaPeptides· batch CP-2605-MOT40

✓ Vendor-published
99.33 %
Jul 2026
Janoshik Analytical Limited

For

MOTS-C

by Verified Peptides· batch M007261420M

COA on file
Aggregated · 3rd-party listing
99.55 %
Jul 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Peptide Plugs· batch 160-04-DK

Aggregated · 3rd-party listing
99.54 %
Jul 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Rescue Research USA· batch RR-MS-2607

Aggregated · 3rd-party listing
99.90 %
Jul 2026
BTLabs Moderate

For

MOTS-c

by VoriLabs· batch MOT-2606-A

Aggregated · 3rd-party listing
99.91 %
Jul 2026
Freedom Diagnostics Moderate

For

MOTS-C

by Peptide Plugs· batch 149-01-DK

Aggregated · 3rd-party listing
99.83 %
Jul 2026
Chromate Moderate

For

MOTS-c

by Arcane Peptides· batch MOT002

Aggregated · 3rd-party listing
99.83 %
Jul 2026
Chromate Moderate

For

MOTS-c

by Moglabs· batch MOT002

✓ Vendor-published
99.83 %
Jul 2026
Chromate Moderate

For

MOTS-c

by Ruo Bio· batch MOT002

COA on file
Research depth

23 citations indexed for MOTS-c

All research on MOTS-c →

review · 2026

MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential

Sepsis-induced cardiomyopathy (SICM) is a prevalent cardiac complication of sepsis that is characterized by inflammatory dysregulation, mitochondrial dysfunction, metabolic disturbance, and changes in the myocardial microenvironment.

Study · 2026

MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide

The mitochondrial DNA (mtDNA) can trigger immune responses and directly entrap pathogens, but it is not known to encode active immune factors. The immune system is traditionally thought to be exclusively nuclear-encoded.

Study · 2026

Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?

Objective MOTS-c is a mitochondria-derived peptide associated with reduced insulin resistance and obesity. The m.1382A>C polymorphism of the MOTS-c gene is linked to an increased risk of type 2 diabetes in men.

animal · 2026

Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model

Type 2 diabetes mellitus (T2DM) is associated with chronic systemic and cardiac inflammation, contributing to the development of diabetic cardiomyopathy.

animal · 2026

MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia

Background Cancer cachexia is a multifactorial metabolic syndrome marked by progressive skeletal muscle loss, reduced function, and increased mortality. Mitochondrial dysfunction is a key driver of this phenotype.

Study · 2026

Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction

Background: Atrial fibrillation (AF) is a common clinical arrhythmia associated with mitochondrial dysfunction, oxidative stress, and atrial fibrosis. Mitochondrial-derived peptides (MDPs), including humanin (HN) and MOTS-c, exhibit cytoprotective properties, but their role in AF remains largely unknown.